| part | subject | predicate | object | published by | date | |
|---|---|---|---|---|---|---|
|
Assertion
|
|
|||||
|
Assertion
|
The purpose of this review is to summarize the current evidence of the off-label use of intravenous (IV) olanzapine and discuss its risks versus benefits for the management of agitation.
|
|
||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|